WARREN, N.J., Aug. 31, 2018 — Celularity, an allogeneic immuno-oncology and placental cell therapeutics company, today announced it entered into a definitive agreement to acquire CariCord, the family cord blood bank established by the University of Colorado and ClinImmune Labs. Through its exclusive ClinImmune Labs relationship, CariCord is the first, and so far the only family cord blood bank to operate inside a FDA Licensed Laboratory. ClinImmune Labs is an academic component of the School of Medicine at the University of Colorado at Denver and Health Sciences Center. Financial details of the transaction were not disclosed. [Read more…]
CariCord Partners with Singapore’s CellResearch Corp to Join “Global Cord Registry” & Launch Cord Tissue Storage in U.S.
Singapore’s CellResearch Corporation has entered into an agreement with CariCord to provide umbilical cord tissue banking services within the United States. CariCord is the private cord blood and tissue banking partner of ClinImmune Labs at the University of Colorado.
As stated in the November 30, 2016, press release:
“CellResearch Corporation Pte Ltd (“CellResearch”), a Singapore-based company that specializes in stem cell technology, through its wholly owned subsidiary, CordLabs Pte Ltd (“CordLabs”), has entered into an agreement with CariCord Inc. (“CariCord”) to provide umbilical cord tissue banking services in the United States. CariCord is the private postnatal cord blood and tissue banking partner of ClinImmune Labs (“ClinImmune”) at the University of Colorado, Anschutz Medical Campus (“UCAMC”).
This agreement extends CellResearch’s on-going collaboration with ClinImmune. The two groups are already working together to obtain US Federal Drug Agency (“US FDA”) approval for Corlicyte™, a drug for the treatment of diabetic wounds. ClinImmune will produce the world’s first Current Good Manufacturing Practices (“cGMP”) cord lining mesenchymal stem cell lines for therapeutic use.”
This license agreement also allows CariCord’s cord tissue clients to join CellResearch’s Global Cord Registry (“GCR”), “a proprietary registry for all clients who have saved cord lining stem cells with licensed partners.” The registry currently has 50,000+ registered clients, making it the largest group of its type in the world.
To learn more, read the full press release from CellResearch Corporation.
Major Industry Alliance: CariCord and ClinImmune Labs Partner with International Space Medicine Consortium
AUTHOR: Authored by Wendy Roberts, PR Director of Orca Communications Unlimited, LLC.
COMMENT BY BIOINFORMANT: Leading global players within cord blood industry frequently attain their industry dominance through industry collaborations. In the announcement below, released May 11, 2015, CariCord and ClinImmune Labs announce a major industry partnership that will study the survivability of umbilical cord blood stem cells under micro gravity (Micro-G) simulation.
CariCord, a private stem cell bank at the University of Colorado, is a FDA-licensed cord blood manufacturer that has processed nearly 9,000 cord blood units and released 700+ for transplantation across 150+ hospitals worldwide. While CariCord is not as substantial in size as other key players within the U.S. cord blood industry (most notably Cord Blood Registry, ViaCord, and Cryo-Cell, respectively) the company is positioning itself for increased visibility and growth through this strategic collaboration. [Read more…]